Digoxin

Generic Name: Digoxin

Brand Names: Digox, Lanoxin

Drug Type: Small Molecule

Chemical Formula: C_₄₁H_₆₄O_₁₄

CAS Number: 20830-75-5

Unique Ingredient Identifier: 73K4184T59

Background: Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954.
...

Indication: Digoxin is indicated in the following conditions: 1) For the treatment of mild to moderate heart failure in adult patients. 2) To increase myocardial contraction in children diagnosed with heart failure. 3) To maintain control ventricular rate in adult patients diagnosed with chronic atrial fibrillation.
...

Associated Conditions: Myocardial contractility, Ventricular Arrhythmia, Mild to moderate heart failure

Associated Therapies: -

Clinical Trials

A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib

Phase 1

Completed

Conditions: Drug-drug Interaction

Interventions: Drug: tucatinib
Drug: repaglinide
Drug: itraconazole
Drug: rifampin
Drug: gemfibrozil
Drug: digoxin
Drug: tolbutamide
Drug: midazolam

First Posted Date: 2018-10-29

Last Posted Date: 2019-12-18

Lead Sponsor: Seagen Inc.

Target Recruit Count: 116

Registration Number: NCT03723395

Locations: 🇺🇸
Covance Clinical Research Unit, Dallas, Texas, United States

IvaBRAdine blocK of Funny Current for Heart Rate Control in permanEnt Atrial Fibrillation. (BRAKE-AF Study).

Phase 3

Completed

Conditions: Atrial Fibrillation
Heart Diseases

Interventions: Drug: Ivabradine
Drug: Digoxin

First Posted Date: 2018-10-24

Last Posted Date: 2022-10-07

Lead Sponsor: Adolfo Fontenla

Target Recruit Count: 68

Registration Number: NCT03718273

Locations: 🇪🇸
Hospital Universitario Puerta de Hierro, Madrid, Spain
🇪🇸
Hospital Universitario de Burgos, Burgos, Spain
🇪🇸
Hospital Clínico San Carlos, Madrid, Spain

and more 7 locations

Inhibition of Sterile Inflammation by Digoxin

Phase 1

Completed

Conditions: Inflammatory Response

Interventions: Other: Placebo
Drug: Digoxin

First Posted Date: 2018-06-18

Last Posted Date: 2024-07-12

Lead Sponsor: Yale University

Target Recruit Count: 45

Registration Number: NCT03559868

Locations: 🇺🇸
Yale Centre of Clinical Investigation, New Haven, Connecticut, United States

Digoxin for Congenital Erythrocytosis Due to Up-Regulated Hypoxia Sensing

Phase 1

Withdrawn

Conditions: HIF-2alpha Erythrocytosis
Erythrocytosis; Familial
PHD2 Erythrocytosis
Polycythemia; Familial
VHL Gene Mutation
Chuvash Erythrocytosis

Interventions: Drug: Digoxin

First Posted Date: 2018-02-15

Last Posted Date: 2023-06-13

Lead Sponsor: University of Illinois at Chicago

Registration Number: NCT03433833

A Study to Evaluate the Effect of Multiple Doses of CC-90001 on the Pharmacokinetics of Omeprazole, Midazolam, Warfarin, Rosuvastatin, Metformin, Digoxin, and Nintedanib in Healthy Adult Subjects

Phase 1

Completed

Conditions: Heathy Volunteer

Interventions: Drug: CC-90001
Drug: Omeprazole
Drug: Nintedanib
Drug: Rosuvastatin
Drug: Metformin
Drug: Midazolam
Drug: Digoxin
Drug: Warfarin
Dietary Supplement: Vitamin K

First Posted Date: 2017-12-06

Last Posted Date: 2019-01-25

Lead Sponsor: Celgene

Target Recruit Count: 56

Registration Number: NCT03363815

Locations: 🇺🇸
Covance Clinical Research Unit, Daytona Beach, Florida, United States

This Study Tests the Effect of Certain Medicines on the Transport of Other Medicines in the Body of Healthy Men

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Digoxin
Drug: Furosemide
Drug: Probenecid
Drug: Metformin
Drug: Rosuvastatin
Drug: Cimetidine
Drug: Verapamil
Drug: Rifampin

First Posted Date: 2017-10-11

Last Posted Date: 2023-11-07

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 45

Registration Number: NCT03307252

Locations: 🇩🇪
CTC North GmbH & Co. KG, Hamburg, Hamburg, Germany

Cardiovagal Baroreflex Deficits Impair Neurovascular Coupling and Cognition in POTS

Early Phase 1

Completed

Conditions: Postural Orthostatic Tachycardia Syndrome (POTS)
POTS
Orthostatic Intolerance

Interventions: Drug: Pyridostigmine
Drug: Digoxin
Drug: Placebo

First Posted Date: 2017-08-25

Last Posted Date: 2022-09-28

Lead Sponsor: New York Medical College

Target Recruit Count: 51

Registration Number: NCT03261570

Locations: 🇺🇸
New York Medical College/Bradhurst building, Hawthorne, New York, United States

Bexagliflozin Drug/Drug Interaction Study With Digoxin

Phase 1

Completed

Conditions: Type2 Diabetes Mellitus

Interventions: Drug: Digoxin
Drug: Bexagliflozin

First Posted Date: 2017-06-23

Last Posted Date: 2021-07-23

Lead Sponsor: Theracos

Target Recruit Count: 20

Registration Number: NCT03197324

Locations: 🇺🇸
Covance CRU, Daytona Beach, Florida, United States

Intrafetal Digoxin as an Adjuvant for Dilation and Evacuation at 20 to 24 Weeks' Gestation

Phase 4

Completed

Conditions: Abortion

Interventions: Drug: Digoxin
Drug: Placebo

First Posted Date: 2017-05-02

Last Posted Date: 2019-10-30

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 178

Registration Number: NCT03136068

Locations: 🇺🇸
Lovejoy Surgicenter, Portland, Oregon, United States
🇺🇸
FPA Women's Health, Long Beach, California, United States
🇺🇸
SFGH Women's Options Center, San Francisco, California, United States

A Drug-Drug Interaction Study to Evaluate Drug Transporter Interactions

Phase 1

Completed

Conditions: Hereditary Angioedema

Interventions: Drug: BCX7353
Drug: Cyclosporine + BCX7353
Drug: Digoxin
Drug: Rosuvastatin
Drug: BCX7353 + digoxin
Drug: rosuvastatin + BCX7353

First Posted Date: 2017-05-02

Last Posted Date: 2017-10-26

Lead Sponsor: BioCryst Pharmaceuticals

Target Recruit Count: 54

Registration Number: NCT03136237

Locations: 🇬🇧
Covance CRU, Leeds, United Kingdom

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy